Research ArticlePsoriatic Arthritis
Open Access

Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study

Tien Nguyen, Melvin Churchill, Robert Levin, Guillermo Valenzuela, Joseph F. Merola, Alexis Ogdie, Ana-Maria Orbai, Jose U. Scher, Arthur Kavanaugh, Farid Kianifard, Chauncy Rollins, Renato Calheiros and Olivier Chambenoit
The Journal of Rheumatology August 2022, 49 (8) 894-902; DOI: https://doi.org/10.3899/jrheum.210912

REFERENCES

  1. 1.↵
    1. Alinaghi F,
    2. Calov M,
    3. Kristensen LE, et al
    . Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 2019;80:251-65.e19.
    OpenUrlPubMed
  2. 2.↵
    1. Mease PJ,
    2. Gladman DD,
    3. Papp KA, et al
    . Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 2013;69:729-35.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Ritchlin CT,
    2. Colbert RA,
    3. Gladman DD
    . Psoriatic arthritis. N Engl J Med 2017;376:2095-6.
    OpenUrlCrossRef
  4. 4.
    1. Gladman DD,
    2. Antoni C,
    3. Mease P,
    4. Clegg DO,
    5. Nash P
    . Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 Suppl 2:ii14-7.
    OpenUrlPubMed
  5. 5.↵
    1. Kavanaugh A,
    2. Helliwell P,
    3. Ritchlin CT
    . Psoriatic arthritis and burden of disease: patient perspectives from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. Rheumatol Ther 2016;3:91-102.
    OpenUrlPubMed
  6. 6.↵
    1. Kane D,
    2. Stafford L,
    3. Bresnihan B,
    4. FitzGerald O
    . A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 2003;42:1460-8.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Haroon M,
    2. Gallagher P,
    3. Fitzgerald O
    . Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis 2015;74:1045-50.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Coates LC,
    2. Helliwell PS
    . Psoriatic arthritis: state of the art review. Clin Med 2017;17:65-70.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Ogdie A,
    2. Schwartzman S,
    3. Husni ME
    . Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol 2015;27:118-26.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Mease PJ,
    2. McInnes IB,
    3. Kirkham B, et al; FUTURE 1 Study Group
    . Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 2015;373:1329-39.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. McInnes IB,
    2. Mease PJ,
    3. Kirkham B, et al; FUTURE 2 Study Group
    . Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;386:1137-46.
    OpenUrlCrossRefPubMed
  12. 12.
    1. Nash P,
    2. Mease PJ,
    3. McInnes IB, et al; FUTURE 3 Study Group
    . Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther 2018;20:47.
    OpenUrlPubMed
  13. 13.
    1. Kivitz AJ,
    2. Nash P,
    3. Tahir H, et al
    . Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study. Rheumatol Ther 2019;6:393-407.
    OpenUrl
  14. 14.↵
    1. Mease P,
    2. van der Heijde D,
    3. Landewé R, et al
    . Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis 2018;77:890-7.
    OpenUrlAbstract/FREE Full Text
  15. 15.
    1. Reich K,
    2. Sullivan J,
    3. Arenberger P, et al
    . Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol 2019;181:954-66.
    OpenUrl
  16. 16.↵
    1. Baraliakos X,
    2. Gossec L,
    3. Pournara E, et al
    . Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis 2021;80:582-90.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Mease PJ,
    2. Kavanaugh A,
    3. Reimold A, et al; FUTURE 1 study group
    . Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5 year efficacy and safety results from the phase 3 FUTURE 1 study. ACR Open Rheumatol 2020;2:18-25.
    OpenUrl
  18. 18.↵
    1. Kivitz A,
    2. Kremer J,
    3. Legerton C, et al
    . Efficacy of secukinumab in a US patient population with psoriatic arthritis: a subgroup analysis of the phase 3 FUTURE studies [abstract]. Arthritis Rheumatol 2019;71 Suppl 10.
  19. 19.↵
    1. Pincus T,
    2. Yazici Y,
    3. Bergman MJ
    . RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin North Am 2009;35:773-8, viii.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Coates LC,
    2. Tillett W,
    3. Shaddick G,
    4. Pincus T,
    5. Kavanaugh A,
    6. Helliwell PS
    . Value of the Routine Assessment of Patient Index Data 3 in patients with psoriatic arthritis: results from a tight-control clinical trial and an observational cohort. Arthritis Care Res 2018;70:1198-205.
    OpenUrl
  21. 21.↵
    1. Vakil-Gilani KM,
    2. Dinno A,
    3. Rich-Garg N,
    4. Deodhar A
    . Routine Assessment of Patient Index Data 3 Score and Psoriasis Quality of Life assess complementary yet different aspects of patient-reported outcomes in psoriasis and psoriatic arthritis. J Clin Rheumatol 2018;24:319-23.
    OpenUrl
  22. 22.↵
    1. Gottlieb AB,
    2. Mease PJ,
    3. Kirkham B, et al
    . Secukinumab efficacy in psoriatic arthritis: individual patient meta-analysis of four phase 3 trials in 2049 patients [abstract]. Arthritis Rheumatol 2018;70 Suppl 10.
  23. 23.↵
    1. Orbai AM,
    2. Husni ME,
    3. Gladman DD, et al
    . Secukinumab efficacy on psoriatic arthritis GRAPPA-OMERACT core domains in patients with or without prior tumor necrosis factor inhibitor use: pooled analysis of four phase 3 studies. Rheumatol Ther 2021;8:1223-1240.
    OpenUrl
  24. 24.↵
    1. Bruin G,
    2. Loesche C,
    3. Nyirady J,
    4. Sander O
    . Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis. J Clin Pharmacol 2017;57:876-85.
    OpenUrlPubMed
  25. 25.↵
    1. Klingberg E,
    2. Bilberg A,
    3. Björkman S, et al
    . Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Res Ther 2019;21:17.
    OpenUrlPubMed
  26. 26.↵
    1. Ogdie A,
    2. Schwartzman S,
    3. Eder L, et al
    . Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations. J Rheumatol 2014;41:2315-22.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

BIOLOGICALS
IL-17 inhibitors
PSORIASIS
PSORIATIC ARTHRITIS

Keywords